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Abstract Interaction of the p85 subunit of PI 3-kinase with the 
insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was inves- 
tigated using the two-hybrid system by assessing for his3 and lacZ 
activation in S. cerevisiae. The experiments were performed with 
the cytoplasmic/3 domain (wild type or mutated) of IR and IGF- 
1R and p85 or its subdomains (N + C-SH2, N-SH2, C-SH2, 
SH3 + N-SH2). The results of his3 activation indicated that p85, 
N + C-SH2 and C-SH2 interact with both IR/] and IGF-1R/3, 
whereas N-SH2 and SH3 + N-SH2 interact only with IRE. In- 
teraction of p85 and N + C-SH2 with IR/3(AC-43) or IGF- 
1R/3(AC-43) in which the C-terminal 43 amino acids (including 
the YXXM motif) were deleted, persisted. The internal binding 
site thus revealed was not altered by further mutating Y~°/F for 
IR or YgS°/F for IGF-1R. Activation of lacZ upon interaction of 
p85 with IR~I(AC-43) was 4-fold less as compared to IR/3. This 
activation with p85 and IGF-1R/3 was 4-fold less as compared to 
IRI~ and was somewhat increased (2-fold) for IGF-1R/3(AC-43). 
Thus, the C-terminal domain in IGF-1R appears to exert a neg- 
ative control on binding of p85 thereby providing a possible regu- 
latory mechanism for direct activation of the PI 3-kinase path- 
way. 
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thereby activates the catalytic p110 subunit [2]. Surprisingly, 
inactivation of the IRS-1 gene in the mouse by using the homol- 
ogous recombination approach did not result in any dramatic 
pathological phenotype, indicating the possible existance of 
alternative signalling pathways [5,6]. 
A number of studies performed mainly with IR have pro- 
vided evidence that some effector proteins such as the p85 
subunit of PI 3-kinase, GTPase activating protein (GAP) and 
SYP (SH2-domain-containing tyrosine phosphatase) could di- 
rectly bind via their SH2 domains to phosphotyrosines of the 
cytoplasmic domain of the receptor [7-11] and this could repre- 
sent an alternative mechanism by which some signalling path- 
ways could be activated or regulated. In IR, the binding site for 
p85 and SYP has been mapped to the C-terminal y1322 and for 
GAP to the NPXY motif at y96o [12]. Interaction of these 
proteins with IGF- 1R has not been examined in detail and only 
weak direct interaction of p85 with IGF-1R has been reported 
[13,141. 
Recently, the two-hybrid approach [15,16] was applied to 
investigate the interaction of IRS-1 with the cytoplasmic fl
domain of IR [17]. In the work reported here, we have used the 
two-hybrid system to perform a comparative analysis of direct 
interaction of p85 with the cytoplasmic fl domain of IR and 
IGF-1R. 
1. Introduction 
The insulin receptor (IR) and IGF-1 receptor (IGF-1R) are 
very homologous in their primary as well as their heterodimeric 
~2~2 structure and belong to the family of membrane receptors 
with tyrosine kinase activity [1]. It is well established that recep- 
tor autophosphorylation upon ligand binding and activation of 
the tyrosine kinase domain are required for most, if not all, of 
the biological effects of insulin and IGF-1. The molecular basis 
of the differential signalling by these two receptors leading to 
common as well as specific biological effects is still not entirely 
understood. One of the mechanisms of signalling by IR and 
IGF-1R consists in the phosphorylation bythe activated recep- 
tor tyrosine kinase of intermediate docking proteins such as 
insulin receptor substrate-1 (IRS-1) and SHC which subse- 
quently bind various Src homology 2 (SH2)-domain containing 
effector proteins that activate different signalling pathways 
[2,3]. For instance, the regulatory p85 subunit of PI 3-kinase 
binds to phosphotyrosines at YXXM motifs [4] in IRS-1 and 
*Corresponding author. Fax: (33) (1) 44 41 24 62. 
Abbreviations: IGF-1, insulin-like growth factor-l; PI 3-kinase, 
phosphatidylinositol 3-kinase; aa, amino acid; C, Cys; H, His; M, Met; 
N, Asn; P, Pro; R, Arg; T, Thr; Y, Tyr; X, any of the 20 aa. 
2. Experimental 
2.1. Plasmid construction 
All Escherichia coli (strain HB 101) and DNA manipulations were 
performed essentially as described [18]. Enzymes used for cloning were 
from Biolabs and Pfu DNA polymerase from Gibco-BRL. Primers 
used for PCR were purchased from Genosys and all 5'-deoxynucleotide 
triphosphates were from Boehringer. Plasmids carrying cloned full- 
length cDNAs encoding IR [19,20] and p85 [21 23] were generously 
provided by A. Ullrich and cloned full-length cDNA for IGF-1R 
[24,25] was obtained from P. De Meyts. The plasmids used for hybrid 
gene constructs were pBTMll6 ([26]; carrying trpl) and pGAD GH 
([27]; carrying leu2), encoding the DNA binding domain of LEXA and 
GAL4 activation domain (GAD), respectively. 
The DNAs corresponding tothe cytoplasmic IRfl and IGF-1Rfl were 
PCR amplified using cloned cDNAs with different sets of the following 
primers (5' to 3'): CGCGAATTCAGAAAGAGGCAGCCAGATGG 
(R1), CGCGGATCCTTAGGAAGGATTGGACCGAG (R2), CGC- 
GAATTCAGAAAGAGAAATAACAGCAG (R3), CGCGGATCC- 
AAGGATCAGCAGGT (R4), CGCGGATCCTTACTCCTCCC- 
TCTGACAGTGCG (R5), CGCGGATCCTTACTTGTGTCCTGA- 
GTGTCTGT (R6),CGCGAATTCAGAAAGAGGCAGCCAGATG- 
GGCCGCTGGGACCGCTTTACGCTTCTTCAAACCCTGAGTT- 
TCTCAG (R7), CGCGAATTCAGAAAGAGAAATAACAGCAG- 
GCTGGGGAATGGAGTGCTGTATGCCTCTGTGAACCCGGA- 
GTTCTTCAG (R8), CGCGGATCCTTAGGTCGAAGACTGGGG- 
CAGCG (R9). The EcoRI and BamHI sites are underlined. The PCR 
products were cloned into pBTM116 using EcoRI/BamHI sites. The 
plasmids obtained by cloning the DNA fragments amplified with the 
primer sets RI/R2, R3/R4, RI/R5, R3/R6, R7/R2, R8/R4 and R3/R9 
encode LEXA hybrid proteins with IRfl, IGF-1Rfl, IRfl(AC-43), IGF- 
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1R13(AC-43), IRfl(AC-43 + y96°/F), IGF-1Rfl(AC-43 + Y95°/F) and 
IGF-1Rfl(CI3371A), respectively. The various forms of the cytoplasmic 
13 domain used are described in section 3.1. 
Several subdomains of p85 were PCR amplified using cloned cDNA 
with different sets of the following primers (5' to 3'): CGCTCTAGA- 
CGGTATGAATAACAATATGTC (P1), CGCGAATTCTTAATCT- 
TCTTTGACAACTTGAT (P2), CGCTCTAGACGAAGATTTGCC- 
CCATCATGA (P3), CGCGAATTCTCATCGCCTCTGCTGTG- 
CAT (P4), CGCTCTAGACAGTGCTGAGGGGTACCAGTA (P5), 
CGCGAATTCTTACCGGGGCTTTGGTGTGGGAG (P6). The 
XbaI and EeoRI sites are underlined. The PCR products cut with 
XbaI/EcoRI were cloned into pGAD GH cut with SpeI/EcoRI. The 
plasmids obtained by cloning the DNA fragments amplified with the 
primer sets P1/P2, P3/P4, P1/P4, P5/P6 and P5/P2 encode GAD hybrid 
proteins with N-SH2 (aa 321~440), C-SH2 (aa 614-725), N + C-SH2 
(aa 321-725), SH3 (aa 2 90) and SH3 + N-SH2 (aa 2~440), respec- 
tively. To engineer a plasmid expressing GAD fusion protein with 
full-length p85, the SacI/ApaI fragment from pRK-p85 was cloned in 
the plasmid encoding GAD hybrid protein with SH3 + N-SH2 cut with 
SacI/ApaI. 
All PCR were performed using Pfu DNA polymerase according to 
the supplier under the following conditions. After an initial denaturing 
step at 95°C for 5 min, 30 cycles were performed each consisting of 
1 min at 95°C, 1 min at 55°C and 2 min at 72°C; the final cycle was 
followed by a further 5 min incubation at 72°C. 
The DNAs for all the recombinant plasmids (two independent clones 
for each construct) were amplified and were used to transform yeast 
cells. 
2.2. Transformation a d growth of yeast 
Yeast strain L40 (trpl-, leu2-, his3-, lexAop-his3, lexAop-lacZ) was 
transformed by the lithium acetate method [28] using different combi- 
nations of plasmids. The transformants were selected on 2% glucose 
minimal agar media lacking Trp and Leu. 
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Fig. 1. Structure of LEXA hybrid proteins with wild type (wt) or 
mutated cytoplasmic 13 domains of IR and IGF-1R (A) and of GAD 
hybrid proteins with p85 or its subdomains (B). 
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Fig. 2. Western immunoblot analysis of protein extracts from yeast 
strains transformed with plasmids encoding LEXA or its hybrid pro- 
teins. Lane h LEXA, Lane 2: LEXA-IR13, Lane 3: LEXA-IGF-1R13, 
Lane 4: LEXA-IRfl(AC-43), Lane 5: LEXA-IGF-1R13(AC-43), Lane 6: 
LEXA-IRfl(AC-43 + y96°/F), Lane 7:LEXA-IGF-1R13(AC-43 + y950/ 
F), Lane 8: LEXA-IGF-1Rfl(C~337/A). The size markers (in kDa) were 
from Bio-Rad. 
2.3. Western immunoblot analysis of hybrid proteins 
Ten milliliters of selective medium (lacking Trp and Leu) with 2% 
glucose were seeded with overnight cultures from colonies of selected 
yeast strains to an optical density at 600 nm of 0.2 and incubated at 
30°C until the optical density reached 0.5. The cells were pelleted, 
resuspended in 400 ,ul of sodium-dodecyl-sulfate (SDS) sample buffer 
and vortexed with glass beads. After centrifugation, the supernanant 
was collected, boiled and 10/A were subjected to SDS-polyacrylamide 
gel electrophoresis [29]. The proteins were blotted to nitrocellulose [30] 
and LEXA hybrid proteins were detected by using an antibody against 
the DNA binding domain of LEXA (obtained from E Moreau) and the 
ECL detection system (Amersham). 
2.4. fl-Galactosidase assays 
The solution fl-galactosidase assays were performed using o-nitro- 
phenyl fl-D-galactopyranoside (ONPG) as substrate and the units of 
13-galactosidase calculated as described [31]. One unit offl-galactosidase 
corresponds to OD420 × 1000/t × v ×p, where t represents minutes of 
the reaction, vis milliliters of supernatant used, andp is protein concen- 
tration in mg/ml. 
3. Results and discussion 
The two-hybrid system represents a genetic approach to 
characterize protein-protein teractions in yeast [15,16]. Basi- 
cally, the two proteins are expressed in yeast as two hybrids: 
one with the DNA binding domain of a transcription factor (i.e. 
LEXA) and other with the activation domain of a transcription 
factor (i.e. GAL4). The yeast strains used possess his3 and/or 
lacZ carrying upstream activating sequences that allow tran- 
scriptional activation of these genes if a functional transcription 
factor is reconstituted upon protein-protein interaction be- 
tween the two hybrids. This approach as been applied here to 
analyse the interaction of the p85 subunit of PI 3-kinase with 
IR and IGF-1R. 
3.1. Engineering and expression of  hybrid proteins 
The DNA binding domain of LEXA was fused to the cyto- 
plasmic fl domain starting from the first aa after the transmem- 
brane domain, i.e. R 94] for IR and R TM for IGF-1R. In the study 
of the interaction of the cytoplasmic fl domain of IR with IRS-1 
using the two-hybrid approach, it was shown that the/3 domain 
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Fig. 3. Growth of yeast strains resulting from his3 activation. Yeast strains cotransformed with plasmids encoding various hybrid proteins grown 
on 2% glucose minimal agar medium lacking Trp and Leu were tested for their ability to grow on the same medium also lacking His. 
is phosphorylated in such a hybrid in the yeast [17]. Hybrids 
of LEXA with fl(AC-43) in which C-terminal 43 aa were deleted 
or with fl(AC-43) further containing Y96°/F mutation for IR and 
Y95°/F for IGF-1R were also engineered (Fig. 1A). In the case 
of IGF-1R, fl(C]337/A) in which the terminal C 1337 was deleted 
was also fused to LEXA. The structure of various GAD hybrid 
proteins with p85 or its subdomains i  shown in Fig. lB. 
Western immunoblot analysis of protein extracts for yeast 
strains transfected with plasmids encoding LEXA or its hybrid 
proteins howed that all the proteins were expressed (Fig. 2). 
We assume that GAD hybrid proteins are also expressed even 
though attempts to detect hese proteins were unsuccessful due 
to high background and unspecific reactions obtained with the 
antibodies against GAD which we used. 
3.2. Interaction of p85 with IR 
Yeast strains coexpressing LEXA-IRfl and GAD hybrid pro- 
teins with p85, N + C-SH2, N-SH2, C-SH2 or SH3 + N-SH2 
initially selected on minimal medium lacking Trp and Leu were 
all able to grow on the same medium also lacking His (Fig. 3). 
Activation of his3 in these transformed strains provides genetic 
evidence that p85 or its subdomains can directly interact with 
IRfl. The growth of yeast strains resulting from such interac- 
tions is comparable tothe growth of a yeast strain coexpressing 
hybrid proteins of LEXA and GAD with RAS and RAF, re- 
spectively (Fig. 3), two proteins that are known to interact 
strongly [26]. The SH3 domain of p85 did not interact with IRfl. 
Finally, no his3 activation was obtained when GAD-p85 was 
coexpressed with hybrid of LEXA with Adhalin ([32]; obtained 
from J. Chelly), a protein unrelated to insulin signalling. 
It is known that the SH2 domains of p85 bind to phosphoty- 
rosines at YXXM motifs [4]. Recently, the binding site of p85 
in IR was mapped to the YTHM motif at y]322 in the C- 
terminal domain on the basis of (i) in vitro precipitation of 
partially purified IR but not of IR deleted for the C-terminal 
43 aa by glutathione-S-transferase fusion proteins containing 
p85 or its subdomains and (ii) the ability of various pY peptides 
to inhibit this precipitation [7,12]. The ability of p85 or its 
subdomains to bind to LEXA-IRfl(AC-43) was thus examined 
(Fig. 3). From his3 activation, it can be concluded that the 
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Fig. 4. fl-Galactosidase activity in protein extracts from yeast strains 
transformed with plasmids encoding GAD-p85 and LEXA hybrid pro- 
teins as indicated. The mean value of at least hree independent exper- 
iments is presented. In each case, the values differed less than 10% from 
one experiment to another. A blank value (~ 10 units) obtained with an 
extract from yeast strain expressing GAD/LEXA had been substracted. 
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interaction of N-SH2, C-SH2 and SH3 + N-SH2 with IRfl is 
indeed abolished upon deleting the C-terminal 43 aa. However, 
p85 and N + C-SH2 continue to interact with IRfl(AC-43) thus 
revealing the presence of a second internal binding site that is 
not capable of binding any of the single SH2 domains used here. 
In a previous tudy examining direct interaction of p85 with 
IR using an immunoprecipitation/cross-linking approach, y960 
was implicated as a possible binding site for p85 [8]. We there- 
fore introduced y96°]F mutation in IRfl(AC-43) and showed 
that this mutation did not have any effect on his3 activation 
using p85 or N + C-SH2 (Fig. 3). 
Interaction of p85 with IRfl as well as with IRfl(AC-43) was 
further examined by analysing activation of lacZ reporter (Fig. 
4). Quantitative analysis howed that activation of lacZ upon 
interaction of p85 with IRfl(AC-43) was decreased 4-fold as 
compared to IRfl. 
3.3. Interaction of p85 with IGF-1R 
Activation of his3 was observed in yeast strains coexpressing 
LEXA-IGF-1Rfl and GAD hybrid proteins with p85, N + C- 
SH2 and C-SH2, indicating direct interaction between p85 and 
IGF-1Rfl (Fig 3). In contrast to what was observed with IRfl, 
no interaction between N-SH2 or SH3 + N-SH2 and IGF-1Rfl 
was detected. 
The cytoplasmic fl domains of IR and IGF-1R are very 
similar [241 and a YAHM motif can also be found at y1316 at 
the C-terminal part of lGF-1R. The ability of p85 or its subdo- 
mains to activate his3 upon binding to IGF-1Rfl(AC-43) indi- 
cates that as for the IRfl(AC-43), p85 and N + C-SH2 continue 
to interact with IGF-1Rfl(AC-43) whereas the binding of C-SH2 
was abolished (Fig. 3). This internal binding was not affected 
when Y95°/F mutation was introduced in IGF-1Rfl(AC-43). 
Interestingly, growth of yeast strains upon his3 activation 
resulting from interaction between p85 and IGF-1Rfl(/IC-43) 
appeared to be higher as compared to IGF-1Rfl. This observa- 
tion was confirmed by analysing lacZ activation that was 2-fold 
higher with p85 and IGF- 1Rfl(AC-43) as compared to IGF- 1 Rfl 
(Fig. 4). Since IGF-1R contains a C residue at the C-terminus 
that is not present in IR, one could imagine that C 1337 might be 
involved in a disulfide bond that could somehow hinder binding 
of p85 to IGF-1R. This was not the case since p85 or its 
subdomains interact equally well with IGF-1Rfl(CI337/A) and 
IGF-1Rfl (Fig. 3). 
3.4. Differential interaction of  p85 with IR and IGF-1R 
A comparative analysis of the interaction of p85 with IRfl 
and IGF-1Rfl using the two-hybrid system indicates that the 
interaction of p85 with IR is much stronger as compared to 
IGF-1R. These results are compatible with previous im- 
munoprecipitation studies that reported only weak interaction 
between p85 and IGF-1R [13,14]. Deletion of the C-terminal 
43 aa in IRfl lead to a decreased interaction with p85 whereas 
in the case of IGF-1Rfl, this deletion rather esulted in a slight 
increase in the interaction with p85. 
In conclusion, it is tempting to speculate that the C-terminal 
domain in IGF-1R might exert a negative control on the bind- 
ing of p85 thereby providing a means of regulating the activa- 
tion of the PI 3-kinase pathway upon its interaction with IGF- 
1R. Such control might represent one of the mechanisms which 
could contribute to achieving specificity in metabolic versus 
mitogenic signalling by these two receptors. In addition, IR and 
IGF-1R appear to contain two sites for the binding of p85: one 
site comprising the C-terminal YXXM motif and a second 
internal site which remains to be characterized. 
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